Ventria Bioscience acquires Meristem Therapeutics' recombinant lactoferrin IP
Ventria Bioscience is acquiring exclusive ownership rights to intellectual property relating to Meristem Therapeutics' recombinant human lactoferrin.
Ventria Bioscience is to acquire intellectual property relating to recombinant lactoferrin developed by French biotechnology company Meristem Therapeutics.
Under the terms of the agreement, Ventria Bioscience will obtain exclusive royalty-free ownership rights for specific patents in the US, France and Canada in exchange for a one-off payment.
The agreement includes patents relating to recombinant human lactoferrin, which is the active ingredient in Ventria Bioscience's lead drug candidate VEN100.
VEN100 is currently being developed as a preventive treatment for antibiotic-associated diarrhoea in high-risk adults.
Scott Deeter, president and chief executive officer of Ventria Bioscience, said: "The patents acquired today cover important components of our product pipeline.
"The decision to purchase this intellectual property is significant because it removes the encumbrance of ongoing royalty and milestone payments, thereby enhancing the future economics of our products that use recombinant human lactoferrin."
Ventria Bioscience has solved the problem of producing commercial-scale yields of recombinant human lactoferrin using its proprietary ExpressTec technology platform.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
.png)
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance